Although resources exist for digital health entrepreneurs looking to raise their first key investment round, industry advice on next steps is harder to find.
The growth of a start-up after obtaining Series A funding is a transformational phase when scaling up the company becomes critical. The CEO can experience pressure to deliver on the revenue growth goals, whilst still developing their product, growing the team, and implementing core processes for the company.
The journey between closing Series A and ‘scale-up’ is one of the hardest, fastest moving company transformation phases – and it requires the most versatile, creative CEOs.
In this webinar, taking place Wednesday 6th April at 15:00 BST / 16:00 CET / 10:00 EDT, we will discuss the challenges CEOs face and their personal journey during this exciting stage of entrepreneurship. Panel discussions will be based around the recent publication The Digital Health Start-up Journey: From Series A to scaling up. There will be live poll questions and an opportunity for audience Q&A.
Our panellists will feature two Series A stage investors and two serial entrepreneurs, who will provide their thoughts and advice. These highly talented and successful individuals will reflect on the main success factors and common characteristics of thriving post-Series A companies.
This webinar will cover:
- Key success factors
- Preparation for life after Series A
- Post-Series A challenges
About the panelists
Madelyn Trupkin Herzfeld, vice chairman and founder of Carevive is an oncology nurse with more than 20 years of experience building oncology focused companies. Before founding Carevive, Madelyn (Maddy) was founder, president, and general manager of the Institute for Medical Education and Research Inc. (IMER). She led the development of accredited oncology medical education programs for nurses, physicians, and others healthcare professionals specializing in oncology.
Tero Silvola is CEO and board member of BC Platforms, and owner of Riverpark Oy, an investment and development company co-operating with five IT and healthcare start-ups. Tero is a serial entrepreneur and founder of companies such as Mawell Oy Ltd, Optomed Oy Ltd (HEL) and Hospital NEO, which has become one of the leading orthopedics hospitals in the Nordics (Mehiläinen Group).
Emanuel Timor, general partner, Vertex Ventures has more than 20 years of experience working with start-up companies and emerging businesses. He joined Vertex Ventures Israel in 1998 and is focusing in the areas of enterprise software and infrastructure and digital health.
Tanja Dowe, is the CEO of Debiopharm Innovation Fund, the strategic investment arm of the Swiss pharmaceutical company Debiopharm. A former entrepreneur and strategy and transaction consultant, she steers the fund to invest in start-ups with disruptive digital health technologies that transform the healthcare and pharmaceutical industries. Over the course of her career, Tanja has worked with more than 80 companies from pre-incorporated start-ups to large global corporates, all of them on the quest of improving healthcare through innovation (see more on LinkedIn).